If you’re asking whether cagrilintide is legal, the short answer is that HHS’s new peptide policy does not cover it. HHS published an interim enforcement discretion policy in the Federal Register on October 30, 2026, and it names six peptides. Cagrilintide is not one of them, and LegitScript describes it as an investigational drug still in clinical trials. Whether any particular sale is lawful depends on the seller’s license and your state, and no source settles that point for cagrilintide. Here is what the rules say, what the research shows, and what to check before you pay anyone.
| Question | What it says |
|---|---|
| Check date | November 2, 2026 |
| Status of cagrilintide | Investigational drug still in clinical trials, according to LegitScript’s September 22, 2026 article |
| Covered by HHS’s six-peptide policy? | No. The policy names BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c |
| HHS policy published | October 30, 2026, in the Federal Register |
| Comment deadline on the policy | November 13, 2026 |
| Price | Prices and bundles change. Ask the prescriber or seller for today’s price and total |
What cagrilintide is, and what it is not
LegitScript, a third-party certification organization, says cagrilintide and retatrutide “remain investigational drugs still in clinical trials and haven’t gone through the advisory committee process at all.” Investigational means the drug is still being studied, not approved for sale. Cagrilintide is therefore not an approved medicine you can get from a pharmacy counter.
It is also not one of the six peptides in HHS’s interim policy. LegitScript’s summary of that policy says it “applies only to the six specified ingredients.”
Who may fit, and who should pause
Federal law allows a compounded drug to be made for “an identified individual patient based on the receipt of a valid prescription order,” if the drug meets the law’s requirements. The text is in 21 U.S.C. 353a on pharmacy compounding. A prescription is only one part of that. LegitScript says a peptide generally needs one of three things to be eligible for compounding: a place on the Section 503A bulks list, a USP or National Formulary monograph, or a role as a component of an FDA-approved drug product. LegitScript also says cagrilintide has not gone through the advisory committee process.
You may want a closer look if a licensed clinician who knows your history walks you through which options apply to you. Pause if anyone offers cagrilintide without a prescription, sells it as a research chemical or supplement, or says it is FDA-approved or legal to sell.
How the HHS policy works, and why cagrilintide is outside it
HHS’s Federal Register notice on the HHS policy was published October 30, 2026, under docket HHS-OASH-2026-0496. Comments close November 13, 2026. LegitScript’s summary lists the six peptides, each in one form and limited routes:
| Peptide | Covered form | Permitted routes |
|---|---|---|
| BPC-157 | Acetate | Subcutaneous, intramuscular, oral, topical |
| TB-500 | Acetate | Subcutaneous, intramuscular |
| Epitalon | Acetate | Subcutaneous, intramuscular |
| Semax | Free base | Intranasal |
| KPV | Acetate | Topical, oral |
| MOTS-c | Acetate | Subcutaneous, intramuscular |
Enforcement discretion is not FDA approval. It does not add these peptides to the 503A bulks list, and FDA may revise or withdraw it at any time, according to LegitScript’s summary.
The policy also sets conditions. It requires a single active ingredient, a patient-specific prescription, FDA-registered sourcing and a certificate of analysis, and the label “This is a compounded drug product. Not for resale.” It excludes 503B outsourcing facilities and products sold as research chemicals or supplements. Separately, LegitScript’s September 22, 2026 article, written before the HHS policy, says that partnering with a separate entity that dispenses or prescribes these substances does not provide a workaround under LegitScript’s certification standards.
What the research shows about cagrilintide
Established facts
Cagrilintide is an investigational drug that is still in clinical trials, per LegitScript. It is not one of the six peptides HHS named.
What regulators and advisers said about peptides in general
ABC News reported on the July 2026 advisory vote on six peptides. It said FDA staff scientists “unanimously opposed every peptide being added to the list, citing a lack of solid clinical trial data, inconsistent recipes from batch to batch and the risk the compounds could trigger harmful immune reactions.” Those six are not cagrilintide. The same report describes the advisers’ vote as non-binding. You can read it in the ABC News report on the July advisory vote.
Our reading
The concern regulators raised about the six peptides was the lack of solid clinical trial data. That is the question to bring to a clinician about cagrilintide: which human trials have been published, how many people took part, and what they found.
Open questions
Which trial reports exist, how many people were studied, and what side effects were recorded are all unanswered in this guide. Ask your prescriber or the trial sponsor for those details before you decide.
Safety, risks and who should avoid it
The FDA’s FDA list of bulk substances with safety risks, updated April 22, 2026, names several peptides for immunogenicity and peptide-related impurities.
The University of Maryland’s University of Maryland guide to compounded drugs says compounded drugs “are not evaluated by the FDA for safety, effectiveness, and quality before they are marketed, and poor quality compounded drugs have led to serious harm.”
ABC News reported that peptides bought as “research chemicals” come with “no doctor involved and no guarantee of what’s in the vial.” Ask your prescriber what side effects the trials recorded before you consider any dose from any source.
Price and what you commit to
Prices and bundles change, so check today’s price directly with the prescriber or seller. Ask for the total you would pay, including any renewal charge, and get the refund and renewal terms in writing before you pay.
Is the seller legitimate? Checks before you pay
- Ask whether the product is one of the six peptides. Cagrilintide is not.
- Watch for claims that the product is FDA-approved or legally permitted for compounding. LegitScript lists “implying or stating that a substance is FDA-approved or otherwise legally permitted for compounding” as a sign that content has crossed into promotion.
- Ask for the pharmacy’s state license and check it with your state board of pharmacy. A legal analysis from Legal 500 notes that “State boards generally oversee the day-to-day practice of state-licensed pharmacies.”
- Ask for the certificate of analysis and the manufacturer’s FDA registration. The policy requires FDA-registered sourcing and a valid certificate of analysis for peptides it covers.
- Check the company name on the label and paperwork against the license you find. The Partnership for Safe Medicines reported in October 2026 that it bought five vials of unapproved peptides from telehealth services, and none of the businesses had the license to dispense injectables in California.
Alternatives, including FDA-approved options and waiting
ABC News notes that some peptide-related medicines, “like insulin and GLP-1s,” are FDA-approved medicines. Pharmaceutical companies have also brought several peptide drugs to market, including insulin, according to The Hill. If you want a medicine that has gone through full FDA review, ask your clinician which approved options fit your situation.
Waiting is also a real option. HHS’s policy is interim, its comment period runs to November 13, 2026, and ABC News reports that formal FDA rulemaking “can take up to a year.” If you are weighing research-grade peptides in general, our guide on are research peptides legal walks through the rules.
Decision table: when to look closer, and when to pause
| May be worth a closer look when | Pause or ask when |
|---|---|
| A licensed clinician who knows your history explains which options apply to you | Someone offers cagrilintide without a prescription |
| You want the published trial results before any decision | A seller calls it a research chemical or supplement |
| The pharmacy shows a state license and FDA-registered sourcing | A seller says it is FDA-approved or legal to sell |
| The refund and renewal terms are written and clear | The seller will not give its license, certificate of analysis or written terms |
How to verify before you pay
Start with your prescriber, not the seller. Take the checklist above to them, and ask them to confirm the pharmacy’s license on your state board’s lookup. Read the refund and renewal terms in full before you give any card number.
Compounded, sold online, or investigational: quick answers
Can it be compounded? Compounding means a pharmacy makes a drug for one patient. Cagrilintide is not among the six peptides HHS named, so the new policy does not cover its compounding.
Can I buy it online? Online sellers offering it sit outside the six-peptide policy. Check them with the steps above.
Why is it outside the HHS policy? The policy applies only to the six named ingredients.
What does investigational mean? It means the drug is still in clinical trials and not approved for sale.
Questions to ask a clinician
- Is cagrilintide covered by the HHS policy for compounding, and if not, what route would apply to me?
- Which published trials exist for cagrilintide, and how many people did they include?
- What side effects did those trials record?
- Which FDA-approved options fit my situation?
For a broader look at the rules for this group of compounds, see our guide to research retatrutide safety and legality guide. The regulatory background is also in the HHS policy appendix on six peptides.
By Gut, Gum and Nail Health Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.